alex revision
August 5th, 2009, 09:12 AM
Rheumatoid arthritis drug ups cancer in kids
Wed, 05 Aug 2009 13:26:16 GMT
http://www.presstv.com/detail.aspx?id=102606§ionid=3510210
FDA officials have warned that a drug commonly prescribed for rheumatoid arthritis can place children and teenagers at an increased risk of developing cancer.
While rheumatoid arthritis patients are believed to be more vulnerable to developing white blood cell cancer, a new report approves the association between using tumor necrosis factor (TNF) blockers and the development of leukemia in these patients.
Anti-TNF drugs, including Simponi (golimumab), Remicade (infliximab), Humira (adalimumab), Cimzia (certolizumab pegol) and Enbrel (etanercept) are commonly prescribed to tackle rheumatoid arthritis and other chronic inflammatory conditions such as Crohn's disease particularly in younger individuals.
According to the recently-released FDA report, TNF blockers are linked to a considerable number of life-threatening cancers in children using the drugs.
The drugs already carry the strongest warnings possible about the risk of possible serious infections. FDA officials, however, urge drug manufacturers to label the medications with the so-called "black box", the strongest warning, for the occurrence of leukemia and new-onset psoriasis.
Wed, 05 Aug 2009 13:26:16 GMT
http://www.presstv.com/detail.aspx?id=102606§ionid=3510210
FDA officials have warned that a drug commonly prescribed for rheumatoid arthritis can place children and teenagers at an increased risk of developing cancer.
While rheumatoid arthritis patients are believed to be more vulnerable to developing white blood cell cancer, a new report approves the association between using tumor necrosis factor (TNF) blockers and the development of leukemia in these patients.
Anti-TNF drugs, including Simponi (golimumab), Remicade (infliximab), Humira (adalimumab), Cimzia (certolizumab pegol) and Enbrel (etanercept) are commonly prescribed to tackle rheumatoid arthritis and other chronic inflammatory conditions such as Crohn's disease particularly in younger individuals.
According to the recently-released FDA report, TNF blockers are linked to a considerable number of life-threatening cancers in children using the drugs.
The drugs already carry the strongest warnings possible about the risk of possible serious infections. FDA officials, however, urge drug manufacturers to label the medications with the so-called "black box", the strongest warning, for the occurrence of leukemia and new-onset psoriasis.